Insmed to Host Third Quarter 2015 Financial Results Conference Call on Friday, November 6, 2015
29 Octobre 2015 - 1:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the needs of patients with rare diseases, today
announced that it will release its financial results for the three
and nine months ended September 30, 2015, before the opening of the
stock market on Friday, November 6, 2015.
Will Lewis, president and chief executive
officer, and Andy Drechsler, chief financial officer, will host a
conference call for investors beginning at 8:30 a.m. ET on Friday,
November 6, 2015 to discuss the third quarter 2015 financial
results and to provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing 877-698-3991 (domestic) or 817-522-1636
(international) and referencing conference ID number 67505047. The
call will also be webcast live on the internet on the company’s
website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through November 20, 2015 by dialing
855-859-2056 (domestic) or 404-537-3406 (international) and
referencing conference ID number 67505047. A webcast of the call
will also be archived for 90 days under the Investor Relations
section of the company’s website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE™
(liposomal amikacin for inhalation) in nontuberculous mycobacteria
(NTM) lung disease, a rare and often chronic infection that can
lead to progressive inflammation and lung damage. There are
currently no products indicated for the treatment of NTM lung
disease in the United States or European Union (EU). In the
EU, the company has filed a marketing authorization application
seeking approval of ARIKAYCE for use in patients with NTM. Insmed’s
earlier-stage pipeline includes INS1009, a nebulized prodrug
formulation of treprostinil that the company is developing for the
treatment of pulmonary arterial hypertension (PAH), a chronic,
life-threatening disorder characterized by abnormally high blood
pressure in the arteries between the heart and lungs. To complement
its internal research, Insmed actively seeks in-licensing
opportunities for a broad range of rare diseases. For more
information, visit www.insmed.com.
Insmed Incorporated:
Susan Mesco
Head of Investor Relations
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024